Opioid dependence treatment extended on the Pharmaceutical Benefits Scheme

Australians dealing with a deadly health problem have been given a major boost with access to the first long-acting treatment extended.

More Australians who are dealing with opioid dependence will be able to access the country’s first long-acting treatment for the problem.

On Sunday, Buvidal’s (buprenorphine) usage as an approved opioid dependence treatment was extended on the Pharmaceutical Benefits Scheme (PBS), with two new approved uses of the medication also included.

Buprenorphine is a prescribed medication that is also used for severe pain and in heroin treatment plans, with over 53,000 Australians currently seeking help through the PBS Opiate Dependence Treatment Program.

Now with the two approved uses, a higher monthly dose of 160mg can be taken, while the daily transition period previously required for patients to go on weekly doses is now gone.

Buprenorphine has been helping Australians dealing with opioid dependence. Picture: Supplied

Past options have made it difficult for patients to adhere to ongoing management, but it is hoped this extension will create more flexibility and help address the barriers surrounding treatment.

Sydney University professor Nick Lintzeris said it was part of “significant changes” Australia has seen in the way opioid dependence is being treated.

“Previously, patients relied on treatments with daily dosing in a clinic or at a pharmacy, which is a huge time commitment and a daily reminder of their condition. This is often a barrier to treatment for people,” he said.

“Now a wider range of weekly and monthly options means anyone with opioid dependence can access individualised treatment, regardless of where they are at in their management journey.”

Up to 110,000 Australians are living with opioid dependence, while in 2019 it accounted for the most drug-induced fatalities with 1129 reported deaths.